OK Biotech Co (TPE:4155) Cyclically Adjusted Revenue per Share: NT$15.05 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4155 OK Biotech Co Ltd TPE:4155
65 GF Score
Price NT$15.80
GF Value NT$27.23
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is OK Biotech Co Cyclically Adjusted Revenue per Share?

OK Biotech Co TPE:4155 -0.63% 65 Cyclically Adjusted Revenue per Share is NT$15.05 as of Dec. 2025. GuruFocus rates TPE:4155 with a GF Score™ of 65/100 and a GF Value™ of NT$27.23 (Possible Value Trap). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

OK Biotech Co's adjusted revenue per share for the three months ended in Dec. 2025 was NT$2.189. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$15.05 for the trailing ten years ended in Dec. 2025.

During the past 12 months, OK Biotech Co's average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of OK Biotech Co was -1.00% per year. The lowest was -1.00% per year. And the median was -1.00% per year.

As of today (2026-07-22), OK Biotech Co's current stock price is NT$15.80. OK Biotech Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$15.05. OK Biotech Co's Cyclically Adjusted PS Ratio of today is 1.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of OK Biotech Co was 2.27. The lowest was 0.86. And the median was 1.56.


OK Biotech Co  (TPE:4155) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

OK Biotech Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.80/15.05
=1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of OK Biotech Co was 2.27. The lowest was 0.86. And the median was 1.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


OK Biotech Co Cyclically Adjusted Revenue per Share Related Terms


OK Biotech Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for OK Biotech Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OK Biotech Co Cyclically Adjusted Revenue per Share Chart

OK Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 15.50 15.14 15.13 15.05

OK Biotech Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.13 15.22 15.26 15.24 15.05

TPE:4155 vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, OK Biotech Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OK Biotech Co Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where OK Biotech Co's Cyclically Adjusted PS Ratio falls into.


TPE:4155
65GF Score
OK Biotech Co Ltd TPE:4155
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OK Biotech Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, OK Biotech Co's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=2.189/324.0540*324.0540
=2.189

Current CPI (Dec. 2025) = 324.0540.

OK Biotech Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 3.193 238.132 4.345
201606 3.262 241.018 4.386
201609 3.512 241.428 4.714
201612 3.884 241.432 5.213
201703 3.757 243.801 4.994
201706 4.267 244.955 5.645
201709 4.516 246.819 5.929
201712 3.119 246.524 4.100
201803 3.458 249.554 4.490
201806 2.942 251.989 3.783
201809 2.958 252.439 3.797
201812 3.479 251.233 4.487
201903 3.225 254.202 4.111
201906 3.528 256.143 4.463
201909 3.169 256.759 4.000
201912 4.419 256.974 5.573
202003 3.962 258.115 4.974
202006 3.370 257.797 4.236
202009 3.332 260.280 4.148
202012 3.989 260.474 4.963
202103 2.626 264.877 3.213
202106 2.829 271.696 3.374
202109 2.688 274.310 3.175
202112 2.804 278.802 3.259
202203 3.301 287.504 3.721
202206 3.738 296.311 4.088
202209 2.595 296.808 2.833
202212 2.237 296.797 2.442
202303 2.415 301.836 2.593
202306 2.544 305.109 2.702
202309 2.126 307.789 2.238
202312 1.892 306.746 1.999
202403 2.359 312.332 2.448
202406 3.010 314.175 3.105
202409 3.214 315.301 3.303
202412 2.863 315.605 2.940
202503 2.827 319.799 2.865
202506 3.000 322.561 3.014
202509 2.629 324.800 2.623
202512 2.189 324.054 2.189

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$15.05 mean?
OK Biotech Co (TPE:4155) has a Cyclically Adjusted Revenue per Share of NT$15.05 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on OK Biotech Co and its competitors.
Is OK Biotech Co's Cyclically Adjusted Revenue per Share too high?
OK Biotech Co's current Cyclically Adjusted Revenue per Share is NT$15.05. Overall, OK Biotech Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
OK Biotech Co's Cyclically Adjusted Revenue per Share of NT$15.05 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on OK Biotech Co and its competitors. OK Biotech Co's current Cyclically Adjusted Revenue per Share is NT$15.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Possible Value Trap. The stock's GF Value™ is NT$27.23, compared to a current price of NT$15.80 — trading 42% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$15.05. OK Biotech Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current Cyclically Adjusted Revenue per Share is NT$15.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OK Biotech Co (TPE:4155) Overvalued in 2026?

Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued. The current stock price of NT$15.80 is trading 42% below its estimated GF Value™ of NT$27.23. GuruFocus considers OK Biotech Co to be Possible Value Trap.

Key valuation signals for TPE:4155:

  • Cyclically Adjusted Revenue per Share: NT$15.05
  • GF Value™: NT$27.23 vs. price of NT$15.80 (42% below fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OK Biotech Co Business Description

Address Gongdao 5th Road, Section 2, No. 91, Hsinchu, TWN, 30070
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
65GF Score

Get the complete analysis for TPE:4155

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.80
Price
NT$27.23
GF Value